Mesoblast Upgraded to Buy From Hold by Jefferies
Mesoblast Share Price Slumps as FY24 Earnings Fail to Impress
Mesoblast FY24 Loss/Shr 8.91c >MESO
Press Release: Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
Mesoblast Posts 21% Decline in Fiscal 2024 Revenue; Loss per Share Narrows
Mesoblast Ltd: Annual Financial Results Presentation
Mesoblast Ltd: Preliminary Final Report including Appendix 4E
2 ASX Healthcare Shares Outperforming Peers on Positive Company News
Investors in Mesoblast (ASX:MSB) Have Seen Impressive Returns of 154% Over the Past Year
Why Brainchip, Gold Road, Mesoblast, and Telix Shares Are Tumbling Today
Express News | Mesoblast Ltd : Piper Sandler Raises to Overweight From Neutral; Raises Target Price to $11 From $4
Why Argosy Minerals, Flight Centre, Mesoblast, and Telix Shares Are Sinking Today
Mesoblast Raised to Overweight From Neutral by Piper Sandler
Mesoblast Price Target Raised to $11.00/Share From $4.00 by Piper Sandler
Mesoblast's Gets FDA Acceptance of Application for Allogeneic Cellular Therapy
Mesoblast Shares Rise on Start of Late-Stage Trial For Low Back Pain Treatment
Express News | Mesoblast - US FDA Accepts Mesoblast's Bla Resubmission for Remestemcel-L
Mesoblast Starts Recruitment for Phase Three Low Back Pain Trial
Up 308% in 6 Months, Why Is the Mesoblast Share Price Tumbling Today?
Mesoblast Refiles Biological License Application With the Us FDA for Cell Therapy; Shares Fall 6%
No Data